Nanocarrier vaccines for SARS-CoV-2.
Adv Drug Deliv Rev
; 171: 215-239, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33428995
The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Carriers
/
Nanocapsules
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Limits:
Animals
/
Humans
Language:
En
Journal:
Adv Drug Deliv Rev
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
Netherlands